“Bozhen Biology” completed the A-round financing of nearly 100 million yuan, led by SDIC

Recently, Bozhen Biotechnology (Suzhou) Co., Ltd. (abbreviation: Bozhen Biotechnology) announced that it has completed a round of financing of nearly 100 million yuan. This round of financing was led by SDIC China Merchants, and the original shareholder Yuanyi Capital followed suit with a disproportionate amount . With the help of this round of financing, Bozhen Bio will further improve the world’s leading organoid CDMO and CRO process technology system, accelerate the construction and operation of commercial production bases, and explore overseas markets.

Bozhen Biology was established in March 2021, and completed the group reorganization in September 2022, with its headquarters based in Suzhou Industrial Park. The company is committed to providing standardized organoid products and integrated technical services, covering three subdivided application scenarios of basic research, precision medicine, and drug research and development. Adhering to the vision of “leading medical innovation and sharing the value of models”, Bozhen Biotech takes the world-class R&D talents as the core, takes “the world’s leading organoid model platform” as the mission, insists on high-quality and efficient services, and effectively improves the R&D of new drugs for customers Efficiency and basic research capabilities allow good medicine to benefit the public earlier.

The company now has a 3000m2 R&D and production base, and has three R&D and operation centers in Suzhou, Shanghai and Dezhou. In 2023, the company’s 10,000m2 large-scale industrialization base will also be fully put into use. At that time, Bozhen Biology will have 4 GMP-B reagent and kit production lines, 6 GMP-C organoid technical service production lines and dozens of clean workshop. Up to now, the company has served more than 300 new drug research and development enterprises, tertiary hospitals, and scientific research institutes, and can provide users with organoid automation equipment, multi-tissue full-process kits, organoid culture and sample library construction technical solutions, and organoid drug research and development. and precision medical subsystems and other products and services.

After this round of financing, Bozhen Bio will continue to strengthen the construction of multi-lineage multi-cancer organ types, gene manipulation, drug discovery and drug efficacy evaluation, experimental animal transplantation and other platform capabilities, comprehensively increase production capacity, and lead the revolution of biomedical multi-field models. This round of financing will also support Bozhen Biotech to expand overseas markets, accelerate the deployment of “end-to-end, global” products and services of its own intellectual property organoid technology, and promote the application of organoids, an emerging technology in the pharmaceutical industry.